

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the periods Q3 2021 – Q2 2022 for the products listed below due to revisions made to its Medicaid pricing data. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Novo Nordisk Inc.'s recalculation affecting certain 340B Covered Entities for the impacted products.

Novo Nordisk Inc. has determined the credit amount owed to each affected Covered Entity. Novo Nordisk Inc will be coordinating with its wholesalers to issue refunds to each affected Covered Entity. Refunds will be issued to a Covered Entity's validated wholesaler pharmacy account when one can be identified.

340B Period	NDC	Product
3Q21	00169280015	SAXENDA
3Q21	00169413013	OZEMPIC 1MG 1X3ML 4PCS.NFPL
3Q21	00169413212	OZEMPIC 0.25MG/0.5MG 6PC.NFPL
3Q21	00169413602	OZEMPIC 1MG 2X1.5ML 4PCS.NFPL
3Q21	00169430313	RYBELSUS 3MG 3X10 TABLETS
3Q21	00169430713	RYBELSUS 7MG 3X10 TABLETS
3Q21	00169431413	RYBELSUS 14MG 3X10 TABLETS
4Q21	00169430313	RYBELSUS 3MG 3X10 TABLETS
4Q21	00169430330	RYBELSUS 3MG TAB BOTTLE
4Q21	00169430713	RYBELSUS 7MG 3X10 TABLETS
4Q21	00169430730	RYBELSUS 7MG TAB BOTTLE
4Q21	00169431413	RYBELSUS 14MG 3X10 TABLETS
4Q21	00169431430	RYBELSUS 14MG TAB BOTTLE
1Q22	00169255013	TRESIBA FLEXTOUCH U200
1Q22	00169430313	RYBELSUS 3MG 3X10 TABLETS
1Q22	00169430330	RYBELSUS 3MG TAB BOTTLE
1Q22	00169430713	RYBELSUS 7MG 3X10 TABLETS
1Q22	00169430730	RYBELSUS 7MG TAB BOTTLE
1Q22	00169431413	RYBELSUS 14MG 3X10 TABLETS
1Q22	00169431430	RYBELSUS 14MG TAB BOTTLE
2Q22	00169430313	RYBELSUS 3MG 3X10 TABLETS
2Q22	00169430330	RYBELSUS 3MG BOTTLES
2Q22	00169430713	RYBELSUS 7MG 3X10 TABLETS
2Q22	00169430730	RYBELSUS 7MG BOTTLES
2Q22	00169431413	RYBELSUS 14MG 3X10 TABLETS
2Q22	00169431430	RYBELSUS 14MG BOTTLES

If a Covered Entity believes it is due a refund and has not seen a credit to its wholesaler account by July 10, 2024, it may contact Novo Nordisk Inc., at NNIBIDNOTIFICATION@novonordisk.com.